Floatz logo

GTI 2040

Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)nucleic_acidPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

43 Active assets in the Blastic Phase Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Imatinib
The University of Hong Kong
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB
Nilotinib
The University of Hong Kong
Phase 2BB

View all 50 →

Same molecule, other indications

GTI 2040 is also rated in:

cancer of unknown primary siteDormant
B
Indicative ·
63 / 100
View asset →
male breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →